KKR Puts Up $1.3B For Clinical Trial Provider PRA

Law360, New York (June 24, 2013, 1:38 PM EDT) -- New York private equity titan KKR & Co. LP on Monday unveiled plans to lift ownership of clinical laboratory testing provider PRA International from fellow investment firm Genstar Capital LLC in a deal reportedly worth $1.3 billion.

The deal will give KKR a top player in outsourced prescription-drug and clinical-trial testing. PRA has more than 50 outposts that cater to pharmaceutical companies around the world and has conducted about 2,000 clinical trials on new products, making it one of the most prominent contract research organizations....
To view the full article, register now.